Generate Biomedicines Financial Statements
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Generate Biomedicines has no annual income statement on file yet, so quarterly figures are shown instead.
Generate Biomedicines revenue and earnings
In the quarter ended Jun 30, 2026, Generate Biomedicines generated $6.3 million in revenue. Generate Biomedicines reported a net loss of $67.3 million. Operating margin was -1134.2%.
Diluted earnings per share came in at -$0.52.
Summary generated from market data by MetaCap's automated system. Methodology
Generate Biomedicines income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Revenue | 6.31M | 7.22M | 10.13M | 8.82M |
| Revenue growth (YoY) | — | — | — | — |
| Operating Expenses | 77.93M | 71.34M | 70.28M | 56.97M |
| Research & Development | 64.33M | 57.81M | 59.73M | 46.83M |
| Operating Income | -71.61M | -64.11M | -60.15M | -48.15M |
| Interest Expense | 155.00K | 182.00K | 307.00K | 368.00K |
| Other Income (Expense) | 4.41M | 2.43M | 3.45M | 3.90M |
| Pretax Income | -67.20M | -61.69M | -56.70M | -44.26M |
| Income Tax | 53.00K | 28.00K | 44.00K | 56.00K |
| Net Income | -67.25M | -61.45M | -52.43M | -41.69M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.52 | -1.07 | -1.94 | -1.62 |
| EPS (Diluted) | -0.52 | -1.07 | -1.94 | -1.62 |
| Shares Outstanding (Basic) | 128.24M | 64.87M | 33.00M | 32.79M |
| Shares Outstanding (Diluted) | 128.24M | 64.87M | 33.00M | 32.79M |
| EBITDA | -68.41M | -60.84M | -56.85M | -44.74M |
| Operating Margin | -1134.21% | -887.49% | -593.78% | -546.09% |
| Net Margin | -1065.17% | -850.58% | -517.56% | -472.73% |
This table shows 4 quarterly periods of Generate Biomedicines's income statement, from Q2 2026 back to Q? 2025, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow GENB's reporting calendar. What is a income statement?